Published on 18 Apr 2024 on Simply Wall St. via Yahoo Finance
Exact Sciences Corporation's (NASDAQ:EXAS) Profit Outlook
With the business potentially at an important milestone, we thought we'd take a closer look at Exact Sciences Corporation's (NASDAQ:EXAS) future prospects. Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. On 31 December 2023, the US$12b market-cap company posted a loss of US$204m for its most recent financial year. The most pressing concern for investors is Exact Sciences' path to profitability – when will it breakeven? Below we will provide a high-level summary of the industry analysts’ expectations for the company.
Check out our latest analysis for Exact Sciences